Pharmacogenomic (PGx) Testing

PGx testing uses a patient's DNA to predict medication response — eliminating trial-and-error prescribing. Learn how PGx works, which patients benefit, and how to integrate it into your practice.

By AJ Pakpour — The Business of Modern Medicine™

Educational Summary

Pharmacogenomic (PGx) testing reads a patient's DNA to predict how they will respond to specific medications — before the first dose is given. It is one of the most clinically impactful precision medicine tools available to providers today.

The science behind PGx is straightforward: your genes encode the enzymes that metabolize most drugs. Variations in these genes mean some patients metabolize drugs too quickly (making standard doses ineffective), too slowly (causing toxic buildup), or not at all. PGx testing identifies these variations so providers can act on them.

The clinical applications span virtually every specialty: psychiatry (antidepressant selection), cardiology (warfarin dosing, clopidogrel selection), pain management (opioid safety), oncology (chemotherapy toxicity risk), and primary care (polypharmacy management).

For practices, PGx testing is both a clinical tool and a revenue opportunity. Testing is reimbursable for many patients, and the clinical value — better outcomes, fewer adverse events, higher patient satisfaction — supports practice differentiation and retention.

Key Takeaways

• ✓PGx testing predicts medication response from a patient's DNA before the first dose
• ✓Key genes include CYP2D6, CYP2C19, CYP2C9 — governing metabolism of hundreds of medications
• ✓Applications span psychiatry, cardiology, pain management, oncology, and primary care
• ✓Testing is reimbursable for many patients under Medicare and commercial insurance
• ✓Results are permanent — a patient's pharmacogenomic profile does not change over their lifetime